Abstract
Ketamine and PCP are commonly used as selective NMDA receptor antagonists to model the putative hypoglutamate state of schizophrenia and to test new antipsychotics. Recent findings question the NMDA receptor selectivity of these agents. To examine this further, we measured the affinity of ketamine and PCP for the high-affinity states of the dopamine D2 and serotonin 5-HT2 receptor and found that ketamine shows very similar affinity at the NMDA receptor and D2 sites with a slightly lower affinity for 5-HT2 (0.5 μM, 0.5 μM and 15 μM respectively), while PCP shows similar affinity for the NMDA and 5-HT2 sites, with a slightly lower affinity for the D2 site (2 μM, 5 μM and 37 μM respectively). Further, ketamine and PCP in clinically relevant doses caused a significant increase in the incorporation of [35S]GTP-γ-S binding in CHO-cells expressing D2 receptors, which was prevented by raclopride, suggesting a partial agonist effect at the D2 receptor. Thus, ketamine and PCP may not produce a selective hypoglutamate state, but more likely produce a non-selective multi-system neurochemical perturbation via direct and indirect effects. These findings confound the inferences one can draw from the ketamine/PCP models of schizophrenia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Laruelle M, Abi-Dargham A . Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies J Psychopharmacol 1999; 13: 358–371
Seeman P, Kapur S . Schizophrenia: more dopamine, more D2 receptors Proc Natl Acad Sci U S A 2000; 97: 7673–7675
Kapur S, Seeman P . Does fast dissociation from the dopamine D2 receptors explain atypical antipsychotic action—a new hypothesis Am J Psychiatry 2001; 158: 360–369
Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B . Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia Neurosci Lett 1980; 20: 379–382
Carlsson M, Carlsson A . Interactions between glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson's disease Trends Neurosci 1990; 13: 272–276
Carlsson A, Waters N, Waters S, Carlsson ML . Network interactions in schizophrenia—therapeutic implications Brain Res Brain Res Rev 2000; 31: 342–349
Javitt DC . Glutamate receptors and schizophrenia: opportunities and caveats Mol Psychiatry 1996; 1: 16–17
Jentsch JD, Roth RH . The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 1999; 20: 201–225
Swerdlow NR, Braff DL, Bakshi VP, Geyer MA . An animal model of sensorimotor gating deficits in schizophrenia predicts antipsychotic drug action In: Csernansky JG (ed) Antipsychotics Heidelberger Platz 3/W-1000 Berlin 33/Germany: Springer-Verlag: Berlin 1996; pp 289–312
Kari HP, Davidson PP, Kohl HH, Kochhar MM . Effects of ketamine on brain monoamine levels in rats Res Commun Chem Pathol Pharmacol 1978; 20: 475–488
Glisson SN, el-Etr AA, Bloor BC . The effect of ketamine upon norepinephrine and dopamine levels in rabbit brain parts Naunyn Schmiedebergs Arch Pharmacol 1976; 295: 149–152
Tsukada H, Harada N, Nishiyama S, Ohba H, Sato K, Fukumoto D et al. Ketamine decreased striatal [(11)C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis Synapse 2000; 37: 95–103
Nabeshima T, Ishikawa K, Yamaguchi K, Furukawa H, Kameyama T . Protection with phencyclidine against inactivation of 5-HT2 receptors by sulfhydryl-modifying reagents Biochem Pharmacol 1988; 37: 3277–3283
Rothman RB . PCP site 2: a high affinity MK-801-insensitive phencyclidine binding site Neurotoxicol Teratol 1994; 16: 343–353
Nishimura M, Sato K, Okada T, Yoshiya I, Schloss P, Shimada S et al. Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells Anesthesiology 1998; 88: 768–774
George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P . The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form Endocrinology 1985; 117: 690–697
Seeman P, Ulpian C, Wreggett KA, Wells JW . Dopamine receptor parameters detected by [3H]spiperone depend on tissue concentration: analysis and examples J Neurochem 1984; 43: 221–235
Liu IS, George SR, Seeman P . The human dopamine D2(Longer) receptor has a high-affinity state and inhibits adenylyl cyclase Brain Res Mol Brain Res 2000; 77: 281–284
Malmberg A, Mohell N . Characterization of [3H]quinpirole binding to human dopamine D2A and D3 receptors: effects of ions and guanine nucleotides J Pharmacol Exp Ther 1995; 274: 790–797
MacKenzie RG, VanLeeuwen D, Pugsley TA, Shih YH, Demattos S, Tang L et al. Characterization of the human dopamine D3 receptor expressed in transfected cell lines Eur J Pharmacol 1994; 266: 79–85
Watanabe M, George SR, Seeman P . Dependence of dopamine receptor conversion from agonist high- to low-affinity state on temperature and sodium ions Biochem Pharmacol 1985; 34: 2459–2463
Lefkowitz RJ, Cotecchia S, Samama P, Costa T . Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins Trends Pharmacol Sci 1993; 14: 303–307
Gardner B, Strange PG . Agonist action at D2(long) dopamine receptors: ligand binding and functional assays Br J Pharmacol 1998; 124: 978–984
Kapur S, Seeman P . Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor Biol Psychiatry 2001; 49: 954–957
Nishimura M, Sato K . Ketamine stereoselectively inhibits rat dopamine transporter Neurosci Lett 1999; 274: 131–134
Martin DC, Introna RP, Aronstam RS . Inhibition of neuronal 5-HT uptake by ketamine, but not halothane, involves disruption of substrate recognition by the transporter Neurosci Lett 1990; 112: 99–103
Martin DC, Adams RJ, Watkins CA . Inhibition of synaptosomal serotonin uptake by Ketalar Res Commun Chem Pathol Pharmacol 1988; 62: 129–132
Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP . Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations Anesthesiology 1998; 88: 82–88
Geisslinger G, Hering W, Thomann P, Knoll R, Kamp HD, Brune K . Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method Br J Anaesth 1993; 70: 666–671
Domino EF, Zsigmond EK, Domino LE, Domino KE, Kothary SP, Domino SE . Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay Anesth Analg 1982; 61: 87–92
Idvall J, Ahlgren I, Aronsen KR, Stenberg P . Ketamine infusions: pharmacokinetics and clinical effects Br J Anaesth 1979; 51: 1167–1173
Shimoyama M, Shimoyama N, Gorman AL, Elliott KJ, Inturrisi CE . Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine Pain 1999; 81: 85–93
Tamminga CA . Schizophrenia and glutamatergic transmission Crit Rev Neurobiol 1998; 12: 21–36
Carlsson M, Carlsson A . Schizophrenia: a subcortical neurotransmitter imbalance syndrome? [Review] Schizophr Bull 1990; 16: 425–432
Hirota K, Okawa H, Appadu BL, Grandy DK, Devi LA, Lambert DG . Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells Anesthesiology 1999; 90: 174–182
Moghaddam B, Adams BW . Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats Science 1998; 281: 1349–1352
Moghaddam B, Adams B, Verma A, Daly D . Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J Neurosci 1997; 17: 2921–2927
Swerdlow NR, Geyer MA . Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia Schizophr Bull 1998; 24: 285–301
Swerdlow NR, Bakshi V, Waikar M, Taaid N, Geyer MA . Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats Psychopharmacol (Berl) 1998; 140: 75–80
Verma A, Kulkarni SK . Modulation of MK-801 response by dopaminergic agents in mice Psychopharmacology 1992; 107: 431–436
Giannini AJ, Eighan MS, Loiselle RH, Giannini MC . Comparison of haloperidol and chlorpromazine in the treatment of phencyclidine psychosis J Clin Pharmacol 1984; 24: 202–204
Giannini AJ, Nageotte C, Loiselle RH, Malone DA, Price WA . Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity J Toxicol Clin Toxicol 1984; 22: 573–579
Giannini AJ, Price WA, Loiselle RH, Malone DW . Treatment of phenylcyclohexylpyrrolidine (PHP) psychosis with haloperidol J Toxicol Clin Toxicol 1985; 23: 185–189
Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet J et al. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat Eur J Neurosci 1999; 11: 4419–4432
Geddes J, Freemantle N, Harrison P, Bebbington P . Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis BMJ 2000; 321: 1371–1376
Yamada S, Harano M, Annoh N, Nakamura K, Tanaka M . Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats Biol Psychiatry 1999; 46: 832–838
Carlsson ML . The selective 5-HT2a receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse—implications for psychosis J Neural Transm—Gen Sect 1995; 100: 225–237
Arvanov VL, Wang RY . M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro Neuropsychopharmacology 1998; 18: 197–209
Wang RY, Liang X . M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice Neuropsychopharmacology 1998; 19: 74–85
Bakshi VP, Geyer MA . Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist J Pharmacol Exp Ther 1997; 283: 666–674
Announcement. Management decisions on priority pipeline products—MDL 100907 In Vision Extra 1999; pp 2–3
Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Riviere ME, Papillon-Downey C . Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia Am J Psychiatry 1999; 156: 419–425
Toth E, Lajtha A . Antagonism of phencyclidine-induced hyperactivity by glycine in mice Neurochem Res 1986; 11: 393–400
Kuribara H, Uchihashi Y . SCH 23390 equivalently, but YM-09151-2 differentially reduces the stimulant effects of methamphetamine, MK-801 and ketamine: assessment by discrete shuttle avoidance in mice Jpn J Pharmacol 1993; 62: 111–114
Jackson DM, Johansson C, Lindgren LM, Bengtsson A . Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats Pharmacol Biochem Behav 1994; 48: 465–471
Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans Psychopharmacol (Berl) 1999; 145: 193–204
Nabeshima T, Ishikawa K, Yamaguchi K, Furukawa H, Kameyama T . Phencyclidine-induced head-twitch responses as 5-HT2 receptor-mediated behavior in rats Neurosci Lett 1987; 76: 335–338
Varty GB, Bakshi VP, Geyer MA . M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats Neuropsychopharmacology 1999; 20: 311–321
Wang RY, Liang X . M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice Neuropsychopharmacology 1998; 19: 74–85
Acknowledgements
We thank Dr H-C Guan for excellent assistance. We thank Professor HA Adams (Medizinische Hochschule Hannover, Germany) for donating a sample of S-ketamine. PS is a Janice Lieber Investigator of NARSAD and SK is supported by a Canada Research Chair in Schizophrenia and Therapeutic Neuroscience. This work was supported by NARSAD, the Ontario Mental Health Foundation, the Canadian Institutes for Health Research, the National Institute on Drug Abuse, the Stanley Foundation and by generous donations from Dr Karolina Jus and the Medland and O'Rorke families.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kapur, S., Seeman, P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors—implications for models of schizophrenia. Mol Psychiatry 7, 837–844 (2002). https://doi.org/10.1038/sj.mp.4001093
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.mp.4001093
Keywords
This article is cited by
-
Endogenous Modulators of NMDA Receptor Control Dendritic Field Expansion of Cortical Neurons
Molecular Neurobiology (2023)
-
Dual action of ketamine confines addiction liability
Nature (2022)
-
Ketamine reduces temporal expectation in the rhesus monkey
Psychopharmacology (2021)
-
Differential effects of glutamate N-methyl-d-aspartate receptor antagonists on risky choice as assessed in the risky decision task
Psychopharmacology (2021)
-
Type of Anaesthetic Influences [11C]MDL100,907 Binding to 5HT2A Receptors in Porcine Brain
Molecular Imaging and Biology (2020)